Norway, May 30 -- Lifecare ASA (LIFE), a medtech company developing next-generation Continuous Glucose Monitoring (CGM) technology, is pleased to announce the selection of its second clinical trial site: the Pfutzner Science & Health Institute (PSHI) in Mainz, Germany.This announcement follows Lifecare's regulatory submission on 20 May 2025 for its first-in-human trial of the CGM implant, and the appointment of Professor Simon Nitter Dankel as Principal Investigator at the Research Unit for Health Surveys (RUHS), University of Bergen, as announced on 27 May 2025.Lifecare's planned clinical trial marks a key milestone on the path toward clinical validation and commercialization. Pending timely regulatory approval, Lifecare expects to finaliz...